Business Context and Reporting Period
Company: Renovaro Inc. (Note: Input metadata referenced "Lunai Bioworks Inc.", but the filing text identifies the registrant as Renovaro Inc., trading symbol RENB).
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2024
Event: Completion of a private placement of equity securities pursuant to Regulation S.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than standard operating financial results. Key transaction metrics include:
- Total Units Sold: 6,421,256 Units (each consisting of one share of Common Stock and one Warrant).
- Warrant Terms: Exercisable for 5 years at $1.4726 per share for one-tenth of a share of Common Stock.
- Total Cash Proceeds: $6,345,071 (Calculated from disclosed cash payments: $5,801,012 + $478,059 + $66,000).
- Debt Conversion: $3,654,929 in aggregate principal and accrued interest of convertible promissory notes were surrendered and terminated in exchange for Units.
- Use of Proceeds: General corporate purposes.
Material Changes Versus Prior Period
This filing reports a discrete financing event and does not provide comparative period financial statements (e.g., revenue or net income changes). The material change is the reduction of outstanding convertible debt by approximately $3.65 million and the issuance of new equity and warrants.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use net proceeds for general corporate purposes. No specific operational guidance or revenue outlook was provided in this filing.
Risks and Contingencies:
- Regulatory Compliance: The offering was made under Regulation S; all investors represented they are not "U.S. persons."
- Dilution: The issuance of 6.4 million units and associated warrants may dilute existing shareholders.
- Unregistered Securities: The securities were sold in a private placement without general solicitation or underwriters.
Important Facts for Investor Verification
- Verify the exact amount of cash proceeds received ($6,345,071) versus the value of debt extinguished ($3,654,929).
- Confirm the impact of the 6,421,256 new shares and warrants on the fully diluted share count.
- Review the specific terms of the Warrants (Exhibit 4.1) regarding exercise conditions and potential cashless exercise provisions.
- Check subsequent filings for the actual deployment of proceeds for "general corporate purposes."